Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Stock Information for Calyxt Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Calyxt Inc.

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting
Cellectis announces the drawdown of the second tranche of Euro15 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis' Shareholders Meeting to be Held on December 22, 2023
Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.